These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 26613954)

  • 1. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    Forslund T; Wettermark B; Hjemdahl P
    Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
    Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
    Simons LA; Ortiz M; Freedman SB; Waterhouse BJ; Colquhoun D; Thomas G
    Curr Med Res Opin; 2016 Nov; 32(11):1857-1861. PubMed ID: 27463735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 10. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
    Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
    Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA
    BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.